Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated strong financial performance in Q4, reflected by a 7% increase in share value in after-market trading and an improved operating margin forecast of at least 750 basis points, suggesting an operating margin exceeding 16%. The company is positioned for future growth through several positive drivers, including new product launches, accelerated adoption in heart and lung transplants, and strong international expansion. Furthermore, TransMedics is establishing a new standard of care in organ transplant therapy, which is expected to enhance value creation and sustain business momentum in the coming years.

Bears say

TransMedics Group Inc. has expressed a negative outlook for its operating margins, forecasting a decline of 250 basis points due to significant investments in its clinical pipeline and international infrastructure. The company experienced mixed results in its product and service revenues, with product revenues of $87.7 million falling short of consensus by approximately $1 million despite a year-over-year growth of 33.1%. Additionally, gross margins weakened, coming in at 58.1%, which is 230 basis points below target, highlighting the challenges the company faces in maintaining profitability amidst competitive pressures and potential adoption risks for its Organ Care System.

TMDX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 9 analysts, TMDX has a Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.